HuBC1-IL12 [105] has been developed to targeted the splice variant extra domain B (ED-B) of fibronectin, which is highly expressed in tumor tissues but few in normal adult tissues with the exception of endometrium; (3) Targeting tumor necrosis. Here, FN1 is linked to neoplasm.